AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CRDF

Cardiff Oncology, Inc.

Price · $CRDFvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CRDF in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CRDF in the last 30 days.

Top stories · $CRDFMore →
MAY 20·Stock TitanMed

[8-K] Cardiff Oncology, Inc. Reports Material Event

Cardiff Oncology, Inc. (CRDF) has filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) to dispute an alleged material breach of their license agreement for the drug onvansertib. NMS claimed breach because Cardiff Oncology did not name an NMS employee as a joint inventor on certain patents and would not agree to file a joint invention continuation patent application. Cardiff Oncology maintains that it did not breach the agreement and that the agreement does not require naming NMS employees on inventions made exclusively by Cardiff Oncology.

JAN 24·ADVFN

CRDF - Trovagene Presents Outlook for Second Half of 2018

Trovagene (NASDAQ: TROV), an oncology therapeutics company, provided an outlook for the second half of 2018, emphasizing progress in two key clinical trials for PCM-075 targeting Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC). The company highlighted significant achievements in the first half of 2018, including encouraging preliminary clinical data and progress in trial enrollments. Trovagene aims to complete dose escalation, present safety/efficacy data, and initiate Phase 2 segments of its AML trial, while also evaluating strategic partnerships and searching for a new CEO.

News on $CRDF

All news →